Escape From Each Of These Approaches That Might Wreck The PF-02341066 Once And For All

3. Results Figure 1 shows the cohort flowchart. We screened 120 patients with AS. Sixty-five patients (54.17%) were excluded because they had normal PFT, 11 (9.17%) with restrictive ventilatory pattern were excluded because they had coexisting asthma, and 8 patients (6.67%) were excluded because they had active infection. Therefore, 36 patients with AS and FVC PF-02341066 manufacturer disease modifying antirheumatic drugs. There were no significant differences between age, gender, disease activity parameters, lung function test results, cardiopulmonary scales, and SGRQ at baseline (Table 1). A small difference, yet not significant, was observed between DMARDs and anti-TNF + DMARDs groups in disease duration (11 years versus 15 years, resp., P = 0.07). In the DMARDs group, 8 patients (40%) were taking methotrexate + sulfasalazine, 5 (25%) sulfasalazine alone, 4 (20%) methotrexate alone, and 2 (10%) methotrexate + azathioprine and 1 patient (5%) received azathioprine alone. In anti-TNF + DMARDs group, 10 patients (62.4%) received etanercept, INCB018424 molecular weight 5 (31.3%) infliximab, and 1 (6.3%) adalimumab; DMARDs prescribed in combination with anti-TNF were methotrexate alone in 4 patients, azathioprine alone in 2, sulfasalazine in 3, and methotrexate + sulfasalazine in 4 patients, methotrexate + azathioprine in 1, sulfasalazine + azathioprine in 1 and methotrexate + sulfasalazine + azathioprine in 1 patient. All patients continued receiving this medication during the AZ191 entire study. Table 1 Comparison of selected variables at baseline between treatment groups. Table 2 shows the secondary outcomes observed in both groups. In the intragroup comparisons at 12 months or 24 months versus baseline there was a significant improvement in all secondary variables in the DMARDs group including BASDAI, BASFI, Post-6MWT Borg scale, 6MWT, and total STGRQ%. Similarly in the intragroup comparison between 12 and 24 months versus baseline in the anti-TNF + DMARDs group a significant improvement was observed in all these variables. Table 2 Secondary outcomes. Intragroup changes of selected clinical variables. 3.1. Comparison of Changes in FVC% Figure 2 shows the increment observed in FVC% from baseline to the end of the follow-up in the group with anti-TNF + DMARDs versus the group with DMARDs alone. A persistent increment in FVC% was observed in both groups, with this improvement in FVC% being higher in the anti-TNF + DMARDs group and statistical significance being observed for the difference (��) of this increment in favor of the anti-TNF + DMARDs since the 6 months (P